Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells $121,677.36 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 18,894 shares of Solid Biosciences stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total value of $121,677.36. Following the sale, the chief operating officer directly owned 97,859 shares of the company’s stock, valued at $630,211.96. This represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Solid Biosciences Price Performance

Shares of NASDAQ SLDB opened at $6.52 on Monday. Solid Biosciences Inc. has a fifty-two week low of $2.41 and a fifty-two week high of $7.37. The stock has a market capitalization of $507.97 million, a PE ratio of -2.62 and a beta of 2.67. The business has a fifty day moving average price of $5.84 and a two-hundred day moving average price of $5.71.

Institutional Trading of Solid Biosciences

Several institutional investors and hedge funds have recently modified their holdings of SLDB. Vestal Point Capital LP grew its holdings in Solid Biosciences by 97.7% during the third quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company’s stock worth $18,356,000 after buying an additional 1,470,000 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock worth $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Geode Capital Management LLC boosted its stake in Solid Biosciences by 184.5% in the second quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock valued at $7,356,000 after acquiring an additional 979,294 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Solid Biosciences by 2,150.4% in the 2nd quarter. Bank of America Corp DE now owns 824,600 shares of the company’s stock worth $4,016,000 after purchasing an additional 787,957 shares during the period. Finally, Woodline Partners LP bought a new stake in shares of Solid Biosciences in the first quarter valued at $2,338,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on SLDB shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a research note on Wednesday, January 14th. Barclays set a $9.00 price target on shares of Solid Biosciences and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Chardan Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Tuesday, November 4th. Finally, Wall Street Zen cut Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.70.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.